Imiphumela Eyisisekelo Yokwelashwa kwe-CD7-Targeted CAR-T ye-T-ALL ne-T-LBL

Ukuhlolwa komtholampilo kwakamuva kubonise inqubekelaphambili ebalulekile ekwelapheni i-T-cell acute lymphoblastic leukemia (T-ALL) ebuyelelwe kabusha noma ye-refractory (T-ALL) kanye ne-T-cell lymphoblastic lymphoma (T-LBL) kusetshenziswa i-CD7-targeted chimeric antigen receptor (CAR) T cell therapy. . Ucwaningo, olwenziwa ithimba leSibhedlela i-Hebei Yanda Lu Daopei kanye ne-Lu Daopei Institute of Hematology, luhilele iziguli ezingu-60 ezithole umthamo owodwa wamaseli e-CD7 CAR (NS7CAR) T akhethiwe ngokwemvelo.

Imiphumela yocwaningo ikhuthaza kakhulu. Ngosuku lwama-28, ama-94.4% eziguli athola ukuxolelwa okuphelele (CR) emnkantsheni. Ukwengeza, phakathi kweziguli ezingama-32 ezinesifo se-extramedullary, ama-78.1% abonise ukusabela okuhle, kwathi ama-56.3% athola ukuxolelwa okuphelele kanye nama-21.9% athola ukuxolelwa kancane. Isilinganiso seminyaka emibili sokusinda kanye nesilinganiso sokuphila ngaphandle kokuqhubekela phambili sibe ngama-63.5% nama-53.7%, ngokulandelana.

Lokhu kwelashwa okusha kuyaphawuleka ngephrofayili yakho yokuphepha elawulekayo, ne-cytokine release syndrome eyenzeka ku-91.7% weziguli (ikakhulukazi i-grade 1/2), kanye ne-neurotoxicity ebonwa ku-5% wamacala. Ngaphezu kwalokho, ucwaningo lwathola ukuthi iziguli ezaqhubeka nokufakelwa kokuhlanganiswa ngemva kokuthola i-CR zazinamazinga okusinda aphezulu kakhulu angenawo ukuqhubeka uma kuqhathaniswa nalawo angazange aphile.

Inkampani yethu iphinde ihlole amandla okwelashwa kwamaseli e-CD7 CAR-T ngomkhiqizo wethu osemthethweni, okuhloswe ngawo ukufaka isandla ekuthuthukisweni kokwelashwa kwezifo ezibulalayo ze-T-cell.

Lokhu okutholakele kugcizelela amandla okwelashwa kwamaseli e-CAR-T ahloselwe i-CD7 ukunikeza ithemba elisha ezigulini ezine-T-ALL ne-T-LBL ehlanekezelwe noma ebuyele emuva, okuphawula ingqopha-mlando empini eqhubekayo yokulwa nalezi zifo eziyinselele.